Aurelia de Pauw
Corporate Officer/Principal bei TETRA BIO-PHARMA INC.
Profil
Aurelia de Pauw is currently the Director at TALLC Corp., Inc. and the Vice President-Clinical Programs & Medical Affairs at Tetra Bio-Pharma, Inc. She graduated from Faculté Universitaire des Sciences Agronomiques de Gembloux with a graduate degree in 2005 and received her doctorate degree from Université de Namur ASBL in the same year.
Aktive Positionen von Aurelia de Pauw
| Unternehmen | Position | Beginn |
|---|---|---|
| TETRA BIO-PHARMA INC. | Corporate Officer/Principal | 01.10.2018 |
TALLC Corp., Inc.
 TALLC Corp., Inc. Pharmaceuticals: MajorHealth Technology TALLC Corp, Inc. operates as a pre-clinical stage pharmaceutical company. It focuses on the development of TA-A001, a novel endocannabinoid CB2 receptor activator with potent anti-inflammatory analgesic properties. The company was founded by Damon Smith, Melanie Kelly and Guy Chamberland and is headquartered in Laval, Canada. | Direktor/Vorstandsmitglied | - |
Ausbildung von Aurelia de Pauw
| Faculté Universitaire des Sciences Agronomiques de Gembloux | Graduate Degree |
| Université de Namur ASBL | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| TETRA BIO-PHARMA INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
TALLC Corp., Inc.
TALLC Corp., Inc. Pharmaceuticals: MajorHealth Technology TALLC Corp, Inc. operates as a pre-clinical stage pharmaceutical company. It focuses on the development of TA-A001, a novel endocannabinoid CB2 receptor activator with potent anti-inflammatory analgesic properties. The company was founded by Damon Smith, Melanie Kelly and Guy Chamberland and is headquartered in Laval, Canada. | Health Technology |
